Loading
Avelumab / Talazoparib / Breast Cancer · Phase 1/2 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 1/2 multi-institutional pilot trial registered at ClinicalTrials.gov with no results yet posted. The study aims to evaluate safety, tolerability, and exploratory immunomodulatory effects of induction talazoparib followed by combination talazoparib and avelumab in advanced breast cancer. No clinical efficacy or outcome data are available from this registry record.
Phase 1/2, Interventional, Single Group, Open label, Treatment purpose. Breast Cancer; age from 18 Years. Intervention: Phase I/Phase II. n = 24. 2 sites: United States.
This is a planned Phase 1/2 multi-institutional pilot trial registered at ClinicalTrials.gov with no results yet posted. The study aims to evaluate safety, tolerability, and exploratory immunomodulatory effects of induction talazoparib followed by combination talazoparib and avelumab in advanced breast cancer. No clinical efficacy or outcome data are available from this registry record.
Primary endpoint is safety and tolerability; no efficacy outcomes are described.
The source did not state who this applies to in practice.
This is an active Phase 1/2 pilot trial with 24 participants designed to assess safety and tolerability; no results are posted in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03964532). This is a study registration, not published results. Lead sponsor: Georgetown University. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 24 participants (ACTUAL). Conditions: Breast Cancer. Interventions: DRUG: Talazoparib; DRUG: Avelumab. Primary outcome measures: Quantification of Grade 3 and 4 toxicities (Adverse Events) , from the start of study drugs through 30 days after end of treatment (approximately 1 year). Brief summary: This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory effects of induction talazoparib followed by the combination of talazoparib and avelumab in patients with advanced breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.